{
  "items": "35",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "(NAMS) Volatility Zones as Tactical Triggers",
      "url": "https://news.stocktradersdaily.com/news_release/16/NAMS_Volatility_Zones_as_Tactical_Triggers_122225123002_1766381402.html",
      "time_published": "20251222T003000",
      "authors": [
        "Robert S.",
        "Thomas H. Kee Jr."
      ],
      "summary": "This article provides an analysis of Newamsterdam Pharma Company N.v. (NASDAQ: NAMS), highlighting weak near and mid-term sentiment that could impact its long-term positive outlook. It details various AI-generated trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry zones, targets, and stop losses. The analysis also covers multi-timeframe signal analysis, showing weak signals in the near and mid-term but a strong signal for the long-term, supported by an exceptional risk-reward setup targeting a 22.2% gain.",
      "banner_image": "https://news.stocktradersdaily.com/media/691351_NAMS_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.914438"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.731325"
        }
      ],
      "overall_sentiment_score": 0.122298,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.120450",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Understanding Momentum Shifts in (NAMSW)",
      "url": "https://news.stocktradersdaily.com/news_release/43/Understanding_Momentum_Shifts_in_NAMSW_121625034402_1765874642.html",
      "time_published": "20251216T034400",
      "authors": [
        "Harold S."
      ],
      "summary": "This article analyzes momentum shifts for Newamsterdam Pharma Company N.v. Warrant (NASDAQ: NAMSW), highlighting a positive near-term sentiment within a long-term strong context, despite a mid-term weak bias. It details an exceptional risk-reward setup targeting a 26.5% gain and outlines three distinct AI-generated trading strategies for different risk profiles. The analysis also provides multi-timeframe signal analysis with support and resistance levels.",
      "banner_image": "https://news.stocktradersdaily.com/media/687128_NAMSW_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.916537"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.607467"
        }
      ],
      "overall_sentiment_score": 0.029318,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.345094",
          "ticker_sentiment_score": "0.036467",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Frazier Life Sciences Management L.P. Has $300.75 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS",
      "url": "https://www.marketbeat.com/instant-alerts/filing-frazier-life-sciences-management-lp-has-30075-million-stock-position-in-newamsterdam-pharma-company-nv-nams-2025-12-13/",
      "time_published": "20251214T100932",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Frazier Life Sciences Management L.P. significantly increased its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) to $300.75 million, representing 14.79% ownership. Institutional investment in NewAmsterdam Pharma is high at nearly 90%, with multiple major funds adding to their positions. While the company missed recent EPS and revenue estimates, analysts maintain a \"Moderate Buy\" rating with an average target price of $45.30.",
      "banner_image": "https://www.marketbeat.com/logos/newamsterdam-pharma-logo-1200x675.jpg?v=20221128141416",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913457"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.816637"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.701633"
        }
      ],
      "overall_sentiment_score": 0.32305,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.341608",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Company N.V. $NAMS Holdings Lifted by Maverick Capital Ltd.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-newamsterdam-pharma-company-nv-nams-holdings-lifted-by-maverick-capital-ltd-2025-12-12/",
      "time_published": "20251213T110911",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Maverick Capital Ltd. significantly increased its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 178.8% in the second quarter, now owning 1.36% of the company. Despite challenging fundamentals, including a recent EPS miss and negative margins, analysts maintain a \"Moderate Buy\" consensus with an average price target of $45.30, with some firms raising their targets. The company is developing obicetrapib for metabolic disease.",
      "banner_image": "https://www.marketbeat.com/logos/newamsterdam-pharma-logo-1200x675.jpg?v=20221128141416",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.923152"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.838699"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.944412"
        }
      ],
      "overall_sentiment_score": 0.02543,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.238409",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BEN",
          "relevance_score": "0.616348",
          "ticker_sentiment_score": "0.224216",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Price-Driven Insight from (NAMS) for Rule-Based Strategy",
      "url": "https://news.stocktradersdaily.com/news_release/150/Price-Driven_Insight_from_NAMS_for_Rule-Based_Strategy_121025104402_1765424642.html",
      "time_published": "20251210T224400",
      "authors": [
        "BY Chris Campbell - Contributor"
      ],
      "summary": "This article provides price-driven insight for Newamsterdam Pharma Company N.v. (NASDAQ: NAMS), highlighting a weak near and mid-term sentiment but a strong long-term positive outlook. It details specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and risk-reward setups. The stock signals are 25.37, 32.27, 35.61, and 39.67, with 39.67 being the target and 32.27 as long-term support.",
      "banner_image": "https://news.stocktradersdaily.com/media/683397_NAMS_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.924526"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.716032"
        }
      ],
      "overall_sentiment_score": 0.256875,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.260401",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Saturn V Capital Management LP Buys 104,342 Shares of NewAmsterdam Pharma Company N.V. $NAMS",
      "url": "https://www.marketbeat.com/instant-alerts/filing-saturn-v-capital-management-lp-buys-104342-shares-of-newamsterdam-pharma-company-nv-nams-2025-12-04/",
      "time_published": "20251206T042301",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Saturn V Capital Management LP significantly increased its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 89.7%, purchasing an additional 104,342 shares to bring its total holdings to 220,695 shares valued at approximately $3.99 million. This makes NAMS the 20th largest position in Saturn V Capital Management LP's portfolio, with institutional ownership of the company standing at nearly 89.9%. Analysts maintain a \"Moderate Buy\" consensus rating with a target price of $45.30, despite a recent EPS miss and negative margins reported by NewAmsterdam Pharma.",
      "banner_image": "https://www.marketbeat.com/logos/newamsterdam-pharma-logo-1200x675.jpg?v=20221128141416",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.924281"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.829217"
        },
        {
          "topic": "finance",
          "relevance_score": "0.730694"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.939026"
        }
      ],
      "overall_sentiment_score": 0.318507,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.321456",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
      "url": "https://uk.finance.yahoo.com/news/newamsterdam-pharma-reports-inducement-grants-210100995.html",
      "time_published": "20251205T210100",
      "authors": [
        "NULL"
      ],
      "summary": "NewAmsterdam Pharma N.V. announced that its Compensation Committee approved inducement share options for two new non-executive hires. These grants, covering an aggregate of 40,000 ordinary shares, are part of the Company's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $39.61 and will vest over four years, contingent on continued employment.",
      "banner_image": "NULL",
      "source": "Yahoo Finance UK",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance UK",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915659"
        }
      ],
      "overall_sentiment_score": 0.145437,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.109216",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
      "url": "https://www.globenewswire.com/news-release/2025/12/05/3200971/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
      "time_published": "20251205T160100",
      "authors": [
        "NULL"
      ],
      "summary": "NewAmsterdam Pharma N.V. announced the grant of inducement share options for 40,000 ordinary shares to two new non-executive hires. These options, granted under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), have an exercise price of $39.61 and will vest over four years, subject to continued employment. This action aims to attract and retain key talent contributing to the company's mission of developing non-statin medicines for cardiovascular disease.",
      "banner_image": "https://ml.globenewswire.com/media/MDA0YzMwMzUtYjU3Zi00MjgyLWI2ZTMtYWZiNzQyZGRjNjY4LTEyNjE4OTQtMjAyNS0xMi0wNS1lbg==/tiny/NewAmsterdam-Pharma-N-V-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.902960"
        },
        {
          "topic": "finance",
          "relevance_score": "0.715590"
        }
      ],
      "overall_sentiment_score": 0.031549,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.308350",
          "ticker_sentiment_score": "0.005293",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - Here's Why",
      "url": "https://www.marketbeat.com/instant-alerts/newamsterdam-pharma-nasdaqnams-shares-gap-down-heres-why-2025-12-03/",
      "time_published": "20251205T120933",
      "authors": [
        "MarketBeat"
      ],
      "summary": "NewAmsterdam Pharma (NASDAQ:NAMS) experienced a significant gap down in its stock price, opening at $36.87 compared to a prior close of $38.33, following an earnings and revenue miss. Despite the negative financial results, analysts maintain a \"Moderate Buy\" consensus with an average target price of $45.30, and several firms have raised their price targets. Insider activity is mixed, with a CAO selling a large number of shares, while institutional investors show increased positions, collectively owning 89.89% of the stock.",
      "banner_image": "https://www.marketbeat.com/logos/newamsterdam-pharma-logo-1200x675.jpg?v=20221128141416",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.941869"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.806033"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.734012"
        }
      ],
      "overall_sentiment_score": 0.012711,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.303312",
          "ticker_sentiment_score": "0.022076",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Company Grants Inducement Share Options to New Hires",
      "url": "https://www.quiverquant.com/news/NewAmsterdam+Pharma+Company+Grants+Inducement+Share+Options+to+New+Hires",
      "time_published": "20251205T091200",
      "authors": [
        "NULL"
      ],
      "summary": "NewAmsterdam Pharma (NAMS) has granted inducement share options for 40,000 ordinary shares to two new non-executive hires under its 2024 Inducement Plan. These options have an exercise price of $39.61, based on the closing market price on December 1, 2025, and will vest over four years. This move aims to attract talent and align employee interests with shareholders as the company continues developing its LDL-lowering therapy, obicetrapib.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.947734"
        },
        {
          "topic": "finance",
          "relevance_score": "0.717196"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.624115"
        }
      ],
      "overall_sentiment_score": 0.104626,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.121770",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "JPMorgan Chase & Co. Increases Stock Position in NewAmsterdam Pharma Company N.V. $NAMS",
      "url": "https://www.marketbeat.com/instant-alerts/filing-jpmorgan-chase-co-increases-stock-position-in-newamsterdam-pharma-company-nv-nams-2025-12-04/",
      "time_published": "20251205T042300",
      "authors": [
        "MarketBeat"
      ],
      "summary": "JPMorgan Chase & Co. significantly increased its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during Q2, purchasing 467,579 additional shares to hold a total of 1,458,897 shares, valued at $26.42 million. While Wall Street analysts maintain a \"Moderate Buy\" rating with an average target price of $45.30, the company's Q3 earnings and revenue missed estimates, and insider transactions show mixed activity. NewAmsterdam Pharma is a biopharmaceutical company focused on developing therapies for metabolic diseases, with obicetrapib in clinical trials.",
      "banner_image": "https://www.marketbeat.com/logos/newamsterdam-pharma-logo-1200x675.jpg?v=20221128141416",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.913528"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.834521"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.949057"
        }
      ],
      "overall_sentiment_score": 0.148286,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.054048",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.823168",
          "ticker_sentiment_score": "0.256939",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.634516",
          "ticker_sentiment_score": "0.348278",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.565110",
          "ticker_sentiment_score": "0.098217",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Franklin Resources Inc. Purchases 78,300 Shares of NewAmsterdam Pharma Company N.V. $NAMS",
      "url": "https://www.marketbeat.com/instant-alerts/filing-franklin-resources-inc-purchases-78300-shares-of-newamsterdam-pharma-company-nv-nams-2025-12-01/",
      "time_published": "20251203T120929",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Franklin Resources Inc. significantly increased its stake in NewAmsterdam Pharma Company N.V., purchasing 78,300 additional shares to own 334,212 shares valued at approximately $6.05 million. This move is part of a broader trend of high institutional ownership in NAMS, despite the company reporting negative EPS and missing revenue expectations. Analysts generally maintain a positive outlook, with an average price target of $44.30.",
      "banner_image": "https://www.marketbeat.com/logos/newamsterdam-pharma-logo-1200x675.jpg?v=20221128141416",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.940888"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.841810"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.913218"
        },
        {
          "topic": "finance",
          "relevance_score": "0.722846"
        }
      ],
      "overall_sentiment_score": 0.1939,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.289764",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BEN",
          "relevance_score": "0.830694",
          "ticker_sentiment_score": "0.234672",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.625568",
          "ticker_sentiment_score": "0.212653",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.590206",
          "ticker_sentiment_score": "-0.050436",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma stock hits all-time high at 41.56 USD",
      "url": "https://www.investing.com/news/company-news/newamsterdam-pharma-stock-hits-alltime-high-at-4156-usd-93CH-4380074",
      "time_published": "20251201T042301",
      "authors": [
        "Investing.com"
      ],
      "summary": "NewAmsterdam Pharma (NAMS) stock has reached an all-time high of $41.56, reflecting a 94.05% increase over the past year and 129.64% over six months, driven by strategic initiatives and promising drug pipeline developments. Despite being moderately overvalued according to InvestingPro data, analysts from Leerink Partners, RBC Capital, and H.C. Wainwright have raised price targets and maintained bullish ratings, highlighting strong investor confidence and the potential of obicetrapib. The company currently has a market capitalization of $4.68 billion with analyst price targets as high as $60.1.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.943203"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.831602"
        }
      ],
      "overall_sentiment_score": 0.601179,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.629293",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December",
      "url": "https://www.globenewswire.com/fr/news-release/2025/11/25/3194271/0/en/NewAmsterdam-Pharma-to-Participate-at-Upcoming-Investor-Conferences-in-December.html",
      "time_published": "20251125T080000",
      "authors": [
        "NULL"
      ],
      "summary": "NewAmsterdam Pharma N.V. announced its management will participate in three upcoming investor conferences in December 2025. Company representatives, including the CFO and CEO, will engage in fireside chats at the 8th Annual Evercore Healthcare Conference, Citi\u2019s 2025 Global Healthcare Conference, and the Piper Sandler 37th Annual Healthcare Conference. Webcasts of these sessions will be available on the company's investor relations website.",
      "banner_image": "https://ml.globenewswire.com/media/MjJiZDUyNGUtNWJjYi00Y2Y3LTlmM2ItMTE4MWNlMjNmMWE1LTEyNjE4OTQtMjAyNS0xMS0yNS1lbg==/tiny/NewAmsterdam-Pharma-N-V-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925380"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.611144"
        }
      ],
      "overall_sentiment_score": 0.221185,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.223411",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December",
      "url": "https://www.globenewswire.com/news-release/2025/11/25/3194271/0/en/NewAmsterdam-Pharma-to-Participate-at-Upcoming-Investor-Conferences-in-December.html",
      "time_published": "20251124T100932",
      "authors": [],
      "summary": "NewAmsterdam Pharma N.V. announced its participation in three upcoming investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference, Citi\u2019s 2025 Global Healthcare Conference, and the Piper Sandler 37th Annual Healthcare Conference. Company management, including the CEO and CFO, will participate in fireside chats at these events. Webcasts of the fireside chats will be available on the company's investor relations website.",
      "banner_image": "https://ml.globenewswire.com/media/MjJiZDUyNGUtNWJjYi00Y2Y3LTlmM2ItMTE4MWNlMjNmMWE1LTEyNjE4OTQtMjAyNS0xMS0yNS1lbg==/tiny/NewAmsterdam-Pharma-N-V-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.731636"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.942205"
        }
      ],
      "overall_sentiment_score": 0.127868,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.137656",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December",
      "url": "https://finance.yahoo.com/news/newamsterdam-pharma-participate-upcoming-investor-130000579.html",
      "time_published": "20251124T042301",
      "authors": [
        "NULL"
      ],
      "summary": "NewAmsterdam Pharma N.V. announced its management will participate in three investor conferences in December 2025. These include the 8th Annual Evercore Healthcare Conference, Citi\u2019s 2025 Global Healthcare Conference, and the Piper Sandler 37th Annual Healthcare Conference. Executives will participate in fireside chats to discuss the company's progress as a late-stage clinical biopharmaceutical firm.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910838"
        }
      ],
      "overall_sentiment_score": 0.219272,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.197927",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NewAmsterdam (Nasdaq: NAMS) to host investor fireside chats at Evercore, Citi, Piper",
      "url": "https://www.stocktitan.net/news/NAMS/new-amsterdam-pharma-to-participate-at-upcoming-investor-conferences-oexqxwppxlb9.html",
      "time_published": "20251124T042301",
      "authors": [
        "NULL"
      ],
      "summary": "NewAmsterdam Pharma (Nasdaq: NAMS) announced that its management will participate in three investor conferences in early December 2025: the 8th Annual Evercore Healthcare Conference, Citi 2025 Global Healthcare Conference, and the Piper Sandler 37th Annual Healthcare Conference. CEO Michael Davidson and CFO Ian Somaiya will be featured in fireside chats. Live webcasts and archived replays of these discussions will be accessible via the company's investor relations website.",
      "banner_image": "https://ml.globenewswire.com/media/MjJiZDUyNGUtNWJjYi00Y2Y3LTlmM2ItMTE4MWNlMjNmMWE1LTEyNjE4OTQtMjAyNS0xMS0yNS1lbg==/tiny/NewAmsterdam-Pharma-N-V-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.934943"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.833613"
        }
      ],
      "overall_sentiment_score": 0.1341,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.130036",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bank of New York Mellon Corp Acquires New Position in NewAmsterdam Pharma Company N.V. $NAMS",
      "url": "https://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-acquires-new-position-in-newamsterdam-pharma-company-nv-nams-2025-11-22/",
      "time_published": "20251121T110924",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Bank of New York Mellon Corp has acquired a new position in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), purchasing 352,952 shares valued at approximately $6.39 million, now owning about 0.31% of the company. Despite significant insider selling by CAO Louise Frederika Kooij, other institutional investors have increased their stakes, and Director James Topper made a purchase. The company has a $4.34 billion market cap, reported negative EPS, but analysts maintain a \"Moderate Buy\" consensus with a target price of $44.30.",
      "banner_image": "https://www.marketbeat.com/logos/newamsterdam-pharma-logo-1200x675.jpg?v=20221128141416",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.933611"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.812395"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.715479"
        }
      ],
      "overall_sentiment_score": 0.045621,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.053585",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BK",
          "relevance_score": "0.710947",
          "ticker_sentiment_score": "0.122360",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating (NASDAQ:NAMS)",
      "url": "https://seekingalpha.com/article/4844341-newamsterdam-obicetrapib-maa-filings-merit-continued-buy-rating",
      "time_published": "20251116T103000",
      "authors": [
        "Terry Chrisomalis"
      ],
      "summary": "NewAmsterdam Pharma retains a \"Buy\" rating due to robust phase 3 results for obicetrapib, which significantly lowers LDL-C. The company's Marketing Authorization Applications for obicetrapib have been accepted by the EMA, paving the way for potential European approval. NewAmsterdam is also exploring expansion into type 2 diabetes and Alzheimer's disease, supported by solid financial reserves and clinical program advancements.",
      "banner_image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2237482639/image_2237482639.jpg?io=getty-c-w630",
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.942366"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.840495"
        },
        {
          "topic": "finance",
          "relevance_score": "0.601371"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.727807"
        }
      ],
      "overall_sentiment_score": 0.71585,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.933191",
          "ticker_sentiment_score": "0.739817",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Achieves Key EMA Regulatory Milestone",
      "url": "https://www.tipranks.com/news/company-announcements/newamsterdam-pharma-achieves-key-ema-regulatory-milestone",
      "time_published": "20251116T100911",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "NewAmsterdam Pharma (NAMS) has reached a significant regulatory milestone with the European Medicines Agency's (EMA) acceptance of marketing authorization applications for obicetrapib, both as a standalone therapy and in a fixed-dose combination with ezetimibe. Despite reporting a decrease in revenue and an increased net loss in its Q3 2025 financial results, the company is advancing its clinical development and building global infrastructure for obicetrapib's potential launch. Analysts currently rate NAMS stock as a Hold with a $36.00 price target, while TipRanks' AI Analyst, Spark, also provides a Neutral rating, noting strong technical momentum but pointing out operational losses and a lack of profitability that impact its valuation.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_390599908-1-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.841376"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.919149"
        }
      ],
      "overall_sentiment_score": 0.299133,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.287516",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
      "url": "https://www.globenewswire.com/news-release/2025/11/07/3183949/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
      "time_published": "20251107T160100",
      "authors": [
        "NULL"
      ],
      "summary": "NewAmsterdam Pharma announced that its Compensation Committee approved the grant of inducement share options for 18,000 ordinary shares to a new non-executive employee. These options, granted under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), have an exercise price of $37.00 and will vest over four years, subject to continued employment. This grant is a material inducement for the employee's acceptance of employment with the biopharmaceutical company.",
      "banner_image": "https://ml.globenewswire.com/media/MDIxNDQ0ZjUtYTJhZS00MTA4LTk4ODMtNDY4OTUyNmJmMDZlLTEyNjE4OTQtMjAyNS0xMS0wNy1lbg==/tiny/NewAmsterdam-Pharma-N-V-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932250"
        }
      ],
      "overall_sentiment_score": 0.043171,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.314535",
          "ticker_sentiment_score": "0.030302",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates",
      "url": "https://finance.yahoo.com/news/newamsterdam-pharma-company-n-v-141503592.html",
      "time_published": "20251105T042301",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "NewAmsterdam Pharma Company N.V. (NAMS) reported a Q3 loss of $0.41 per share, missing the Zacks Consensus Estimate of a $0.38 loss, and revenues of $0.35 million, significantly lagging the $29.11 million from the prior year and the consensus estimate. The company's shares have outperformed the S&P 500 year-to-date, but its immediate stock movement will depend on management's commentary and future earnings expectations. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/zf_1wpp4e4lihErpE5wvzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNjtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2020-11/3bc15d30-250e-11eb-bffb-472fe5eb11fe",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.924794"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.825586"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.705247"
        }
      ],
      "overall_sentiment_score": -0.283129,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.263734",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Newamsterdam Pharma stock hits all-time high at 39.76 USD By Investing.com - Investing.com South Africa",
      "url": "https://za.investing.com/news/company-news/newamsterdam-pharma-stock-hits-alltime-high-at-3976-usd-93CH-3922402",
      "time_published": "20251015T153629",
      "authors": [
        "Investing.com"
      ],
      "summary": "The article reports that Newamsterdam Pharma's stock has reached an all-time high of 39.76 USD. However, the rest of the page indicates an application error, suggesting the full content of the article is not currently available.",
      "banner_image": null,
      "source": "Investing.com South Africa",
      "category_within_source": "General",
      "source_domain": "Investing.com South Africa",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.928476"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.704199"
        }
      ],
      "overall_sentiment_score": 0.002946,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.313732",
          "ticker_sentiment_score": "0.000257",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation - Stock Titan",
      "url": "https://www.stocktitan.net/news/NAMS/caristo-chosen-by-leading-pharma-company-as-worldwide-imaging-core-74z5q7s5mw9q.html",
      "time_published": "20251014T110000",
      "authors": [],
      "summary": "Caristo Diagnostics has been selected as the worldwide imaging core laboratory for NewAmsterdam Pharma's REMBRANDT Cardiovascular Imaging Trial. Caristo will be responsible for measuring coronary plaque and inflammation across 50 sites in 7 countries, utilizing its proprietary FAI-Score technology. The trial aims to assess the efficacy of obicetrapib+ezetimibe fixed-dose combination on coronary plaque burden, with primary and secondary endpoints related to plaque volume and inflammation.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.038235,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.301217",
          "ticker_sentiment_score": "0.041691",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation (2025-10-14) - Seeking Alpha",
      "url": "https://seekingalpha.com/pr/20264205-caristo-chosen-by-leading-pharma-company-as-worldwide-imaging-core-lab-to-measure-coronary",
      "time_published": "20251014T110000",
      "authors": [],
      "summary": "Caristo Diagnostics has been selected as the worldwide imaging core lab for NewAmsterdam Pharma's REMBRANDT clinical trial. Caristo will utilize its CaRi-Heart\u00ae and CaRi-PlaqueTM technologies to measure coronary inflammation and plaque burden, as well as monitor changes over time. This partnership underscores the growing pharmaceutical interest in Caristo's capabilities for evaluating new drugs' effects on cardiovascular health.",
      "banner_image": null,
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.024393,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.333076",
          "ticker_sentiment_score": "0.026501",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Major Phase 3 Data Coming: NewAmsterdam's Novel Cholesterol Drug Results at ESC Congress 2025",
      "url": "https://www.stocktitan.net/news/NAMS/new-amsterdam-pharma-to-participate-in-upcoming-medical-meeting-and-ah6kf5m9xcbx.html",
      "time_published": "20250825T110924",
      "authors": [
        "NULL"
      ],
      "summary": "NewAmsterdam Pharma (NASDAQ: NAMS) will present pooled safety and efficacy data from its Phase 3 BROADWAY and BROOKLYN trials for obicetrapib at the European Society of Cardiology Congress in Madrid from August 29 to September 1, 2025. Additionally, company management will participate in three investor conferences in September 2025, including Citi\u2019s Biopharma Back to School Summit, Cantor Global Healthcare Conference, and Wells Fargo Healthcare Conference. Obicetrapib is an oral, low-dose, once-daily CETP inhibitor being developed to lower LDL-C in patients at risk of cardiovascular disease.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930538"
        }
      ],
      "overall_sentiment_score": 0.14746,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.126223",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site",
      "url": "https://www.prnewswire.com/news-releases/piramal-pharma-solutions-and-newamsterdam-pharma-invest-in-dedicated-suite-to-enhance-oral-solid-dosage-production-capabilities-at-piramals-sellersville-pennsylvania-site-302535566.html",
      "time_published": "20250821T024100",
      "authors": [],
      "summary": "Piramal Pharma Solutions and NewAmsterdam Pharma have invested in a dedicated oral solid dosage (OSD) form suite at Piramal's Sellersville, Pennsylvania facility. This multi-million-dollar investment enhances the site's capabilities for fixed dose combination (FDC) products, specifically for NewAmsterdam Pharma's investigational non-statin cholesterol medication. The new suite aims to improve operational efficiency and meet future commercial demand for the FDC, demonstrating an integrated approach to development across Piramal's global facilities.",
      "banner_image": "https://mma.prnewswire.com/media/1726186/Piramal_Pharma_Solutions_Logo.jpg?w=200",
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.837665"
        }
      ],
      "overall_sentiment_score": 0.020871,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.328896",
          "ticker_sentiment_score": "0.031100",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results",
      "url": "https://www.globenewswire.com/news-release/2025/08/06/3128171/0/en/NewAmsterdam-Pharma-Provides-Corporate-Update-and-Reports-Second-Quarter-Financial-Results.html",
      "time_published": "20250806T070000",
      "authors": [],
      "summary": "NewAmsterdam Pharma announced its second-quarter 2025 financial results and provided a corporate update, highlighting significant progress with its drug obicetrapib. Key updates include the European marketing authorization application on track for 2H25, the PREVAIL Phase 3 CVOT remaining on schedule, and positive late-breaking data from BROADWAY and TANDEM trials, including an Alzheimer's disease analysis showing obicetrapib significantly reduced plasma p-tau217 levels. The company also reported revenue of $19.1 million and a net loss of $17.4 million for the quarter, while maintaining a strong cash position of $783.3 million.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/f7b8b881-9461-4712-9965-707ed3bdd573?size=3",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.920064"
        }
      ],
      "overall_sentiment_score": 0.038414,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.306205",
          "ticker_sentiment_score": "0.030799",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Shareholders Will Probably Not Have Any Issues With NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) CEO Compensation",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/shareholders-will-probably-not-have-any-issues-with-newamste",
      "time_published": "20250529T000000",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "NewAmsterdam Pharma's CEO Michael Davidson's compensation of US$6.5m for 2024, including a US$621.3k salary, is largely in line with industry averages for biotechs of similar market capitalization. Despite a 44% decrease in EPS over three years, the company has seen a 76% total shareholder return and 587% revenue growth, suggesting shareholders will likely approve the compensation at the upcoming AGM. While the revenue growth is strong, some shareholders might seek improved EPS growth before further increasing CEO pay.",
      "banner_image": "https://images.simplywall.st/asset/chart/685404834-ceo-compensation-1-dark-2/1748513574436",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914911"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.808222"
        },
        {
          "topic": "finance",
          "relevance_score": "0.603244"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.507969"
        }
      ],
      "overall_sentiment_score": 0.012404,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.303590",
          "ticker_sentiment_score": "0.018584",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia",
      "url": "https://www.globenewswire.com/news-release/2024/12/10/2994358/0/en/NewAmsterdam-Pharma-Announces-Positive-Topline-Data-from-Pivotal-Phase-3-BROADWAY-Clinical-Trial-Evaluating-Obicetrapib-in-Patients-with-Atherosclerotic-Cardiovascular-Disease-and-.html",
      "time_published": "20241210T070000",
      "authors": [],
      "summary": "NewAmsterdam Pharma announced positive topline results from its Phase 3 BROADWAY clinical trial for obicetrapib, showing a statistically significant 33% reduction in LDL-C (p<0.0001) in patients with ASCVD and/or HeFH. The trial also observed a 21% reduction in major adverse cardiovascular events (MACE) favoring obicetrapib and reported a well-tolerated safety profile comparable to placebo. These findings support obicetrapib's potential as an effective treatment for patients whose LDL-C is not adequately controlled by existing therapies.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.947689"
        }
      ],
      "overall_sentiment_score": 0.809428,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.848821",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH",
      "url": "https://www.globenewswire.com/news-release/2024/11/20/2984300/0/en/NewAmsterdam-Pharma-Announces-Positive-Topline-Data-from-Pivotal-Phase-3-TANDEM-Clinical-Trial-Evaluating-the-Fixed-Dose-Combination-of-Obicetrapib-10-mg-and-Ezetimibe-10-mg-in-Pat.html",
      "time_published": "20241120T070000",
      "authors": [
        "NULL"
      ],
      "summary": "NewAmsterdam Pharma announced positive topline data from their Phase 3 TANDEM clinical trial, which evaluated a fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg. The trial met all co-primary endpoints, demonstrating a significant reduction in LDL-C by approximately 50% compared to placebo, and was well-tolerated. These results support future global regulatory filings for the drug combination in patients with ASCVD or HeFH whose LDL-C is not adequately controlled.",
      "banner_image": "NULL",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914315"
        }
      ],
      "overall_sentiment_score": 0.513026,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.501722",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/newamsterdam-pharma-company-nv-nasdaqnams-surges-13-private",
      "time_published": "20241114T000000",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) saw its stock surge by 13%, benefiting private equity firms that hold 46% of the shares, alongside institutional investors. Private equity firms, as the largest owners, stand to gain the most from stock increases and wield significant influence over company strategy. The article details the ownership structure, highlighting the substantial stakes held by private equity, institutional investors, hedge funds, and specific large shareholders.",
      "banner_image": null,
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.916426"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.814898"
        },
        {
          "topic": "finance",
          "relevance_score": "0.716475"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.936701"
        }
      ],
      "overall_sentiment_score": 0.40511,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.404844",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership",
      "url": "https://finance.yahoo.com/news/while-institutions-own-29-newamsterdam-121834153.html",
      "time_published": "20240907T000000",
      "authors": [
        "editorial-team@simplywallst.com (Simply Wall St)"
      ],
      "summary": "Private equity firms hold 47% ownership in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), making them the largest shareholder group, while institutional investors own 29%. The top five shareholders collectively control 56% of the company, giving them significant influence over decision-making. Insiders also own a substantial amount of shares, aligning their interests with other shareholders.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.938585"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.704153"
        }
      ],
      "overall_sentiment_score": 0.044401,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "0.316032",
          "ticker_sentiment_score": "0.048288",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
      "url": "https://finance.yahoo.com/news/newamsterdam-pharma-reports-inducement-grants-203200963.html",
      "time_published": "20240906T203200",
      "authors": [
        "NewAmsterdam Pharma N.V."
      ],
      "summary": "NewAmsterdam Pharma announced the grant of inducement share options to three new non-executive hires, as approved by its Compensation Committee. These options, covering 111,000 ordinary shares, were granted under the 2024 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4). The exercise price is $15.91 per share, with vesting over four years.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.912429"
        },
        {
          "topic": "finance",
          "relevance_score": "0.712884"
        }
      ],
      "overall_sentiment_score": 0.148838,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.124034",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September",
      "url": "https://www.stocktitan.net/news/NAMS/new-amsterdam-pharma-to-participate-in-upcoming-investor-conferences-klkiz4frvtqx.html",
      "time_published": "20240830T080000",
      "authors": [],
      "summary": "NewAmsterdam Pharma (Nasdaq: NAMS) announced its participation in two upcoming investor conferences in September. Management will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5-6, 2024, and the Cantor Global Healthcare Conference on September 17, 2024. Live webcasts and replays of both events will be available on the company's investor relations website.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924549"
        }
      ],
      "overall_sentiment_score": 0.145546,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NAMS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.120090",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}